Swiss National Bank
VKTX icon

Swiss National Bank’s Viking Therapeutics VKTX Stock Holding History

Swiss National Bank’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.62M Buy
220,900
+8,400
+4% +$271K ﹤0.01% 1120
2026
Q1 		$6.91M Buy
212,500
+1,800
+0.9% +$57.9K ﹤0.01% 1155
2025
Q4 		$7.41M Buy
210,700
+3,900
+2% +$138K ﹤0.01% 1131
2025
Q3 		$5.43M Buy
206,800
+3,100
+2% +$92.5K ﹤0.01% 1285
2025
Q2 		$5.4M Buy
203,700
+9,400
+5% +$247K ﹤0.01% 1252
2025
Q1 		$4.69M Sell
194,300
-1,900
-1% -$60K ﹤0.01% 1299
2024
Q4 		$7.9M Buy
196,200
+2,400
+1% +$137K 0.01% 1060
2024
Q3 		$12.3M Buy
193,800
+200
+0.1% +$11.7K 0.01% 840
2024
Q2 		$10.3M Buy
193,600
+25,000
+15% +$1.64M 0.01% 898
2024
Q1 		$13.8M Buy
168,600
+1,000
+0.6% +$44.5K 0.01% 768
2023
Q4 		$3.12M Sell
167,600
-29,900
-15% -$391K ﹤0.01% 1590
2023
Q3 		$2.19M Sell
197,500
-8,500
-4% -$122K ﹤0.01% 1784
2023
Q2 		$3.34M Buy
206,000
+39,100
+23% +$819K ﹤0.01% 1563
2023
Q1 		$2.78M Buy
+166,900
New +$1.72M ﹤0.01% 1630
2022
Q2 		– Sell
-166,500
Closed -$500K – 2794
2022
Q1 		$500K Buy
166,500
+11,200
+7% +$40.2K ﹤0.01% 2606
2021
Q4 		$714K Hold
155,300
– – ﹤0.01% 2579
2021
Q3 		$975K Buy
155,300
+10,100
+7% +$62.4K ﹤0.01% 2448
2021
Q2 		$870K Sell
145,200
-4,800
-3% -$28.5K ﹤0.01% 2528
2021
Q1 		$949K Buy
150,000
+3,000
+2% +$21.1K ﹤0.01% 2360
2020
Q4 		$828K Hold
147,000
– – ﹤0.01% 2367
2020
Q3 		$856K Hold
147,000
– – ﹤0.01% 2168
2020
Q2 		$1.06M Buy
147,000
+22,600
+18% +$150K ﹤0.01% 2067
2020
Q1 		$582K Hold
124,400
– – ﹤0.01% 2116
2019
Q4 		$998K Buy
124,400
+4,800
+4% +$35K ﹤0.01% 2140
2019
Q3 		$823K Hold
119,600
– – ﹤0.01% 2155
2019
Q2 		$993K Buy
119,600
+2,400
+2% +$20.5K ﹤0.01% 2113
2019
Q1 		$1.17M Buy
117,200
+5,600
+5% +$46.9K ﹤0.01% 1988
2018
Q4 		$854K Buy
+111,600
New +$1.33M ﹤0.01% 2092

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Swiss National Bank's VKTX Position: Q2 2026 in Review

Swiss National Bank increased its Viking Therapeutics (VKTX) stake by 4% in Q2 2026, buying an estimated $271K and bringing the position to 220,900 shares worth $8.62M. The position accounts for ﹤0.01% of the portfolio, ranked #1120.

Swiss National Bank first reported a position in VKTX in Q4 2018 and has held it in 28 quarters since. The position peaked at $13.8M in Q1 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Swiss National Bank held 220,900 shares of Viking Therapeutics worth $8.62M as of Q2 2026.
  • Swiss National Bank bought 8,400 Viking Therapeutics shares in Q2 2026, an estimated $271K.
  • Viking Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1120 holding.
  • Swiss National Bank first reported a position in Viking Therapeutics in Q4 2018 and has held it in 28 quarters since.
  • Swiss National Bank's Viking Therapeutics position peaked at $13.8M in Q1 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.